## International Continence Society

August 22-26, 1999

29th Annual Meeting
Video
Demonstration

Denver, Colorado USA<sup>4</sup>

Ref. No. 307

Category No.

# **Abstract Reproduction Form B-1**

Author(s):	S C Radley, C R Chapple, NP Bryan, D Craig D E Clarke			
	Double Spacing			
Institution City Country	Royal Hallamshire Hospital, Sheffield, UK			
	Double Spacing			
Title (type in	EFFECTS OF METHOXAMINE ON MAXIMUM URETHRAL PRESSURE II			
CAPITAL	WOMEN WITH GENUINE STRESS INCONTINENCE :			
LETTERS)	A PLACEBO CONTROLLED, DOUBLE BLIND CROSSOVER STUDY.			

#### Aims of Study

To evaluate the potential role for a selective  $\alpha_i$ -adrenoceptor agonist in the treatment of stress urinary incontinence, we conducted a clinical pharmacological study utilising methoxamine in women with genuine stress incontinence (GSI).

### Methods

In a randomised, placebo controlled, double blind crossover study, half log incremental doses of intravenous methoxamine or placebo (saline) were administered to a group of six women (mean age 46 years, range 38 - 55) with GSI. Resting maximum urethral pressure (MUP), blood pressure, heart rate and symptomatic side effects were simultaneously measured.

#### Results

Methoxamine caused a significant rise in systolic blood pressure, no significant increase in diastolic blood pressure and a significant fall in heart rate at the maximum dose (lmg/70kg/min). A non-significant rise in MUP was evoked (figures 1 - 4). Systemic side effects including piloerection, headache and cold extremities were reported by all 6 subjects and persisted for up to 18 hours in 2 women.

	Baseline (mean <u>+</u> SEM)	Methoxamine (1 mg/70 kg/min) (mean <u>+</u> SEM)	% change	p value*
Diastolic BP (mmHg)	64.7 ± 3.35	71.0 ± 3.10	+ 9.7	0.1462
Systolic BP (mmHg)	126.1 ± 9.25	154.4 = 8.31	+22.4	<0.0001
Pulse (beats/min)	73.9 ÷ 3.85	55.6 ±10.21	-24.8	0.0002
Max Urethral Pressure (cmH <sub>2</sub> O)	89.2 ± 8.37	109.3 ± 15.73	+22.5	0.1159

\*Using repeated measures ANOVA.

## Conclusions

The results indicate that given the non-significant effect on urethral pressure, with associated piloerection and cardiovascular side-effects, the clinical usefulness of direct, peripherally acting subtype-selective a<sub>1</sub>-adrenoceptor agonists in the medical treatment of stress incontinence may be limited